Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088793178> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2088793178 abstract "Clodronate is a bisphosphonate effective in the prevention and treatment of osteoporosis in postmenopausal women. Non-adherence to bisphosphonates, however, is a major issue in clinical practice. Simplifying dose regimens may increase compliance.To assess bioequivalence between an intramuscular (i.m.) clodronate 200 mg/lidocaine 1% twice-a-month formulation and a clodronate 100 mg/lidocaine 1% weekly formulation in 32 postmenopausal women.In this double-blind, randomized, two-way crossover study, test and reference formulations were administered in single dose, with a 2-week wash-out between administrations. The primary endpoint was clodronic acid cumulative excretion in the first 24 hours after injection (Xu0-24h). Cumulative excretion in the 72 hours post-dose (Xu0-72h) and maximum excretion rate (Ratemax) were also evaluated. Bioequivalence was assumed if the 90% confidence intervals (CIs) of the geometric means ratios of the dose-normalized parameters were within the 80.00 - 125.00% range. Local tolerability was evaluated.Mean Xu0-24h values were 114.03 ±23.13 mg and 55.22 ±9.73 mg for clodronate 200 mg and 100 mg. The 90% CIs for dose-normalized Xu0-24h, Xu0-72h and Ratemax ere 95 -110%, 94 -107% and 95 - 113%. Local tolerability of both treatments was good. The differences in pain intensity between formulations were not sigificantly different at most assessment times. Headache was the only treatment-related adverse event.Bioequivalence of the two formulations was confirmed in terms of dose-normalized rate and amount of clodronic acid excretion. This result, together with the favorable tolerability of the novel 200 mg formulation, suggests the possibility of reducing the number of i.m. administrations from once-a-week to twice-a-month." @default.
- W2088793178 created "2016-06-24" @default.
- W2088793178 creator A5027823359 @default.
- W2088793178 creator A5028877971 @default.
- W2088793178 creator A5033328049 @default.
- W2088793178 creator A5058977793 @default.
- W2088793178 creator A5082249757 @default.
- W2088793178 date "2013-04-01" @default.
- W2088793178 modified "2023-09-23" @default.
- W2088793178 title "Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given twice monthly, in comparison with i.m. disodium clodronate 100 mg/lidocaine 1%, given weekly, in healthy postmenopausal female patients" @default.
- W2088793178 doi "https://doi.org/10.5414/cp201799" @default.
- W2088793178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23357844" @default.
- W2088793178 hasPublicationYear "2013" @default.
- W2088793178 type Work @default.
- W2088793178 sameAs 2088793178 @default.
- W2088793178 citedByCount "2" @default.
- W2088793178 countsByYear W20887931782014 @default.
- W2088793178 countsByYear W20887931782020 @default.
- W2088793178 crossrefType "journal-article" @default.
- W2088793178 hasAuthorship W2088793178A5027823359 @default.
- W2088793178 hasAuthorship W2088793178A5028877971 @default.
- W2088793178 hasAuthorship W2088793178A5033328049 @default.
- W2088793178 hasAuthorship W2088793178A5058977793 @default.
- W2088793178 hasAuthorship W2088793178A5082249757 @default.
- W2088793178 hasConcept C10146269 @default.
- W2088793178 hasConcept C112705442 @default.
- W2088793178 hasConcept C126322002 @default.
- W2088793178 hasConcept C126894567 @default.
- W2088793178 hasConcept C142724271 @default.
- W2088793178 hasConcept C197934379 @default.
- W2088793178 hasConcept C204787440 @default.
- W2088793178 hasConcept C27081682 @default.
- W2088793178 hasConcept C2778375690 @default.
- W2088793178 hasConcept C42219234 @default.
- W2088793178 hasConcept C42404028 @default.
- W2088793178 hasConcept C44249647 @default.
- W2088793178 hasConcept C71924100 @default.
- W2088793178 hasConcept C87813604 @default.
- W2088793178 hasConcept C98274493 @default.
- W2088793178 hasConceptScore W2088793178C10146269 @default.
- W2088793178 hasConceptScore W2088793178C112705442 @default.
- W2088793178 hasConceptScore W2088793178C126322002 @default.
- W2088793178 hasConceptScore W2088793178C126894567 @default.
- W2088793178 hasConceptScore W2088793178C142724271 @default.
- W2088793178 hasConceptScore W2088793178C197934379 @default.
- W2088793178 hasConceptScore W2088793178C204787440 @default.
- W2088793178 hasConceptScore W2088793178C27081682 @default.
- W2088793178 hasConceptScore W2088793178C2778375690 @default.
- W2088793178 hasConceptScore W2088793178C42219234 @default.
- W2088793178 hasConceptScore W2088793178C42404028 @default.
- W2088793178 hasConceptScore W2088793178C44249647 @default.
- W2088793178 hasConceptScore W2088793178C71924100 @default.
- W2088793178 hasConceptScore W2088793178C87813604 @default.
- W2088793178 hasConceptScore W2088793178C98274493 @default.
- W2088793178 hasLocation W20887931781 @default.
- W2088793178 hasLocation W20887931782 @default.
- W2088793178 hasOpenAccess W2088793178 @default.
- W2088793178 hasPrimaryLocation W20887931781 @default.
- W2088793178 hasRelatedWork W2014215308 @default.
- W2088793178 hasRelatedWork W2038119104 @default.
- W2088793178 hasRelatedWork W2048588916 @default.
- W2088793178 hasRelatedWork W2095024445 @default.
- W2088793178 hasRelatedWork W2116753857 @default.
- W2088793178 hasRelatedWork W2131666897 @default.
- W2088793178 hasRelatedWork W2184652695 @default.
- W2088793178 hasRelatedWork W2205641460 @default.
- W2088793178 hasRelatedWork W2431224659 @default.
- W2088793178 hasRelatedWork W2792233399 @default.
- W2088793178 isParatext "false" @default.
- W2088793178 isRetracted "false" @default.
- W2088793178 magId "2088793178" @default.
- W2088793178 workType "article" @default.